NCT03028701View on ClinicalTrials.gov

Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Copd
Interventions
DRUG

Formoterol/Budesonide 12/400 mcg Discair

Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®

Trial Locations (1)

34020

Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Neutec Ar-Ge San ve Tic A.Ş

INDUSTRY

NCT03028701 - Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD | Biotech Hunter | Biotech Hunter